Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LQDA | Performance Stock Units | Award | $0 | +221K | $0.00 | 221K | Jan 11, 2024 | Common Stock | 221K | Direct | F6, F7 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. |
F2 | 25% of the RSUs shall vest on January 11, 2025 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. |
F3 | Includes 5,384 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. |
F4 | The securities are held by Roger A. Jeffs Living Trust UAD 2/29/2000 (the "Trust"). The Reporting Person is the trustee of the Trust. |
F5 | The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |
F6 | Each performance stock unit ("PSU") converts into one share of the Issuer's common stock. |
F7 | On January 11, 2024, the Reporting Person was granted 221,338 PSUs. The PSUs shall vest upon the later of (A) the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter and (B) the first commercial sale of YUTREPIA by the Issuer. |